Reduction of daunomycin toxicity by razoxane
- PMID: 7248163
- PMCID: PMC2010720
- DOI: 10.1038/bjc.1981.127
Reduction of daunomycin toxicity by razoxane
Abstract
A single dose of 200 mg/kg razoxane protected mice against the subchronic lethal effects (i.e. within 21 days) of 10 mg/kg daunomycin. When the razoxane dose was split into 2 doses of 100 mg/kg, even better protection against higher doses of daunomycin was obtained. The best protective effect was seen when the razoxane was given 24 h before or simultaneously with the daunomycin, and it was still present, though less, 24 h later. Histopathological examination to determine the site of protection showed it to be in the small bowel. Marrow and cardiac tissue showed no evident changes when examined by light microscopy.
Similar articles
-
Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters.Res Commun Chem Pathol Pharmacol. 1983 May;40(2):217-31. Res Commun Chem Pathol Pharmacol. 1983. PMID: 6410471
-
Effect of razoxane (ICRF 159) on daunomycin (NSC 82151) metabolism and DNA complexation.Drug Chem Toxicol. 1980;3(2):213-25. doi: 10.3109/01480548009108284. Drug Chem Toxicol. 1980. PMID: 7227218
-
Mitigating effects of ICRF-159 (razoxane) on a daunomycin-induced cardiomyopathy in mice.Drug Chem Toxicol. 1982;5(2):155-64. doi: 10.3109/01480548209017776. Drug Chem Toxicol. 1982. PMID: 7128476
-
Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds.Adv Pharmacol Chemother. 1982;19:249-90. doi: 10.1016/s1054-3589(08)60025-3. Adv Pharmacol Chemother. 1982. PMID: 6819768 Review. No abstract available.
-
Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.Semin Oncol. 1998 Aug;25(4 Suppl 10):22-30. Semin Oncol. 1998. PMID: 9768820 Review.
Cited by
-
Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine).Cancer Chemother Pharmacol. 1991;28(4):235-40. doi: 10.1007/BF00685528. Cancer Chemother Pharmacol. 1991. PMID: 1879040
-
Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.Drugs. 1999 Mar;57(3):293-308. doi: 10.2165/00003495-199957030-00003. Drugs. 1999. PMID: 10193684 Review.
-
Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.Br Heart J. 1993 Aug;70(2):185-8. doi: 10.1136/hrt.70.2.185. Br Heart J. 1993. PMID: 8038032 Free PMC article. Clinical Trial.
-
Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.Cancer Chemother Pharmacol. 1993;32(6):445-9. doi: 10.1007/BF00685888. Cancer Chemother Pharmacol. 1993. PMID: 8258192
-
Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.Cancer Chemother Pharmacol. 1990;26(3):193-7. doi: 10.1007/BF02897198. Cancer Chemother Pharmacol. 1990. PMID: 2357766
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources